Market Opportunity Non-Small Cell Lung Cancer (NSCLC)
NSCLC is leading cause of cancer death
Median patient survival is 8 months in Stage IV
U.S. Prevalence(1): 175,000 (Stage IIIB and IV)
U.S. Incidence(1): 72,000 (Stage IIIB and IV)
Est. Cost of Therapy: $10,000-12,000
U.S. Market Potential: $1.75+ billion
(1) Source: Future Oncology, June 15, 2000